Latest1 information on COVID-19
©2022 Stanford Medicine
Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation
Recruiting
I'm InterestedTrial ID: NCT04994249
Purpose
To identify diagnostic and prognostic biomarker signatures of recovery versus having
persisting high-impact chronic pain and functional disability in adults with Chronic
Musculoskeletal Pain.
Official Title
Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation
Stanford Investigator(s)
Sean Mackey, M.D., Ph.D.
Redlich Professor, Professor of Anesthesiology, Perioperative, and Pain Medicine and, by courtesy, of Neurology
Eligibility
Inclusion Criteria:
- 1) Inclusion criteria: Adults (18-80 years; ~64% female expected based on clinic
distribution) with chronic MSP as categorized by the World Health Organization (WHO).
Exclusion Criteria:
- 1) Chronic musculoskeletal pain (MSP) explained by inflammatory disease (e.g.,
rheumatoid arthritis, lupus) or CP with a primary diagnosis other than chronic MSP
(e.g., neuropathic pain), (2) significant cognitive impairment, (3) MRI
contraindication, (4) medical or psychiatric problems interfering with the study, (5)
current medicolegal factors (e.g., open disability claim), (6) plans for surgery
during the study, (7) pregnancy and (8) Children under the age of 18 will not be
included in the study.
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Anne Cunniffe Marcy, MSBH
650-721-6931